Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 6/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359691 | 0.82 | METAP2 (0.47) | DHFRTLR8TSHRKDM4EALDH1A1 | |
| SCHEMBL1507925 | 0.77 | MCHR1 (0.40) | MCHR1TLR8HTR3ATSHR | |
| SCHEMBL1784500 | 0.76 | DHFR (0.44) | DHFRKDM4EALDH1A1 | |
| SCHEMBL1507775 | 0.76 | PDE10A (0.46) | DHFRALDH1A1 | |
| SCHEMBL15886634 | 0.76 | NCF1 (0.56) | DHFRTLR8 | |
| SCHEMBL28508426 | 0.73 | KCNH2 (0.49) | MCHR1TLR8HTR3A | |
| SCHEMBL28123841 | 0.72 | KCNH2 (0.56) | DHFRMCHR1TLR8HTR3A | |
| SCHEMBL12827741 | 0.69 | METAP2 (0.46) | TLR8TSHRKDM4EALDH1A1 | |
| SCHEMBL26053800 | 0.68 | PARP1 (0.58) | MCHR1TLR8HTR3AKDM4E | |
| SCHEMBL230460 | 0.65 | METAP2 (0.59) | HTR3ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107987016-B | Crystal of compound N-butyl-2, 2' -imino-bis (8-quinolinamine), pharmaceutical composition and application thereof | 广州威尔曼新药研发有限公司 | 2022-05-27 | — | — | CN | claimed |
| EP-1919894-B1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED SA (FR) | 2014-10-08 | — | — | EP | claimed |
| US-8324196-B2 | Polyquinoline derivatives and the therapeutic use thereof | PALUMED S.A. (FR) | 2012-12-04 | — | — | US | claimed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | claimed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | claimed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | claimed |
| CN-116598501-A | Composite lithium-rich material, preparation method thereof, positive electrode and secondary battery | 深圳市德方创域新能源科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-107987016-B | Crystal of compound N-butyl-2, 2' -imino-bis (8-quinolinamine), pharmaceutical composition and application thereof | 广州威尔曼新药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-107987016-B | Crystal of compound N-butyl-2, 2' -imino-bis (8-quinolinamine), pharmaceutical composition and application thereof | 广州威尔曼新药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-107987016-B | Crystal of compound N-butyl-2, 2' -imino-bis (8-quinolinamine), pharmaceutical composition and application thereof | 广州威尔曼新药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2018076245-A1 | CRYSTAL OF BIS(8-QUINOLINAMINE) DERIVATIVES | GUANGZHOU WELMAN NEW DRUG R&D CO., LTD. (CN) | 2018-05-03 | — | — | WO | disclosed |
| EP-1919894-B1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED SA (FR) | 2014-10-08 | — | — | EP | disclosed |
| EP-1919894-B1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED SA (FR) | 2014-10-08 | — | — | EP | disclosed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| EP-1919894-A2 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | Palumed SA (FR) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007015017-A2 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | HTT, APP, PSEN1 | DHFR 3469/4885MCHR1 3521/4885TLR8 4852/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | DHFR 1426/4885MCHR1 3156/4885TLR8 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.